SexyMD review

The shortest term and lowest headline are different offers

SexyMD's GLP-1 program lists $269 for its four-week plan, with advertised equivalents of $249, $229, and $199 on twelve-, twenty-four-, and forty-eight-week commitments. The GLP-1/GIP program lists $369 for four weeks and $349, $329, and $299 across the longer choices. These terms are expressed in weeks, not interchangeable calendar months. The lowest headline belongs to a forty-eight-week commitment rather than a flexible single-month purchase at that amount.

Ask for the exact full obligation and payment schedule before selecting a longer plan. The twenty-four- and forty-eight-week plans ship every twelve weeks, which describes delivery rather than necessarily proving the billing interval. A forty-eight-week term is also shorter than a calendar year. Do not turn the listed equivalent into a payable annual total without the service confirming its charge basis. The order should make the financial commitment, medication quantity, and renewal authorization clear together.

Product identity needs a plain answer

The product pages use GLP-1 and GLP-1/GIP categories rather than prominently naming the molecules. The terms use general mechanism language rather than independently establishing that the products are semaglutide and tirzepatide. Receive a direct prescription-specific answer before paying. Ask for the actual drug, formulation, concentration, and supplied quantity. A mechanism label is not enough to identify what is being dispensed, particularly when comparing a named-drug offer from another service or transferring an existing prescription.

The pricing is presented by commitment length rather than a dose ladder. Confirm that the quoted rate applies to your actual prescription and ask what happens if the clinician changes it during a paid term. A price structure is not a recommended progression or evidence that every patient should use the same dose. Compounded drugs are not FDA approved, and a familiar ingredient name does not establish equivalence to a branded finished medicine. Obtain product-specific storage and written instructions from the actual pharmacy.

Separate testimony from product evidence

The same three testimonials appear on both product pages, including a dual-agonist account displayed with the other program. A repeated testimonial does not establish that the experience applies to each medication, and it is not a clinical trial. The wider claim of more than 800 women likewise lacks a clear source or methodology. Evaluate the actual prescription and follow-up arrangement rather than using social proof to predict your results or resolve which product a category name represents.

SexyMD identifies SexyMD LLC, a Nevada limited liability company, with a Las Vegas address and an email contact. That provides corporate identification without establishing an office visit or the credentials of the assigned clinician. It describes dispensing through 503A and 503B pharmacies without clearly naming the actual dispenser. Ask for the medical practice, treating professional, and pharmacy location. A facility category does not itself verify the finished product or explain who answers a personal clinical question.

Support and geography still need confirmation

The company claims all-state availability and offers financing. Confirm the specific prescription and location, and read any financing agreement separately from the treatment terms. Installments change payment timing, not the underlying obligation. Ask how a cancellation or refund affects both arrangements and what happens to remaining shipments if treatment cannot continue. A longer commitment can lower the advertised equivalent while making an early stop more financially consequential.

SexyMD may interest someone prepared to evaluate a commitment-based compounded program, but the molecule identification and actual payment schedule need especially clear answers. Its broader sexual-health business does not establish specialist pregnancy, breastfeeding, or postpartum expertise. Discuss relevant circumstances and coordination with existing care directly. Choose on the confirmed prescription, full term, accessible follow-up, and written exit conditions, with four-week charges kept distinct from longer-plan equivalents and the lowest headline never presented as a standalone monthly rate.